Biomarkers Market – Market Outlook & Trends
The Global Biomarkers Market was assessed at USD 40.1 billion in 2019 and might reach USD 101.2 billion by 2026, at a CAGR of 14.2 %, over the forecast period. Development in the global biomarkers the industry is mainly driven by reasons such as increasing diagnostic applications of biomarkers, increasing R&D funding for pharma and biotech companies, a growing number of CROs, and low cost of clinical trials in emerging countries, the high occurrence of cancer, and new initiatives for research. On the other hand, high capital savings and low cost-benefit ratio poorly suitable regulatory and repayment systems, and technical issues related to sample group and storage are the significant elements confining the development of this market?
Biomarkers Market – Overview
A biomarker is a material that can be presented among
creatures to inspect organ functions or other features of their health. A biomarker is objectively evaluated and measured as an indication of typical
pathogenic processes, biological processes, or pharmacologic responses to
therapeutic interventions. Biomarkers indicate a wide variety of illnesses or
health features along with the type or level of contact to genetic
susceptibility to environmental exposure, environmental factor, genetic
responses markers of clinical or subclinical diseases, and pointers of response
the usage of biomarkers in cancer treatment
Biomarkers are used in application areas such as companion diagnostics, personalized medicines, and other diagnostic measurements, including drug discovery and growth and disease risk assessment. These growing diagnostic uses of biomarkers are predictable to drive market growth in the coming years. Companion diagnostics and biomarkers have become progressively pertinent in the practice of medicine, foremost to improved diagnosis, dealing, and monitoring across several disease areas. It can be used to recognize patients likely to reply well to certain drugs or cure options. These diagnostics are often used with a specific drug.
Technological advancements have permitted the grouping of biomarkers with novel drugs for precise diagnosis and following cure options. For instance, biomarkers can be functional for the cure of several neurological diseases by stalking brain health and activity by examining biomolecules. Nascent developments, such as biomarker signatures, have augmented the treatment rate of nervous disorders resulting in early diagnosis, non-invasive testing, and rapid drug development.
Biomarkers Market: Segmentation
Based on type, the biomarkers market is segmented into safety, efficacy, and validation biomarkers. The effectiveness biomarkers segment is additionally categorized into pharmacodynamic, predictive, surrogate, and prognostic biomarkers.
In 2016, the safety biomarkers section accounted for the leading share of the biomarkers market. However, the usefulness biomarkers segment is projected to record the highest CAGR during the prediction period. The efficacy biomarkers segment is predictable to register the highest growth during the forecast period, chiefly due to the wide variety of products obtainable in the market and the growing acceptance of these biomarkers for various applications.
By application, the personalized medicine segment is expected to grow at the highest CAGR during the forecast period. Biomarkers are mainly used in disease risk assessment, diagnostics, drug discovery & development, personalized medicine, and other applications (DNA fingerprinting, ecotoxicology, and forensics). The use of biomarkers for the analysis of complex diseases, including neurological disorders, cancer, cardiovascular disorders, is increasing. This primary factor drives the growth of the investigative segment of the biomarker market. However, with rising demand for custom-designed treatment plans for diseases like cancer, the personalized medicine segment is expected to witness the highest development in the forecast period.
By disease indication, the cardiovascular disorder segment is expected to grow at the highest CAGR during the forecast period. Biomarkers are widely used in the analysis and management of multiple diseases. Physiological levels of biomarkers also alteration depend upon the administration of drugs. The study of numerous biomarkers helps clinicians make meaningful choices about the diagnosis, disease stage, therapy plan, and forecast in patients.
Based on the disease indication, this report falls into cancer, cardiovascular disorders, neurological illnesses, immunological disorders, and other illness indications. Cancer forms the most significant segment primarily due to the growing occurrence of disease internationally and the increasing use of biomarkers in cancer diagnostics.
Geographically, the Global Biomarkers Market falls into North America, Europe, Asia-Pacific, and LAMEA regions.
Biomarkers Market: Regional insights
North America conquered the biomarkers market globally in 2018 and is likely to remain leading over the forecast period as well. This local dominance can be attributed to the regional occurrence of major pharmaceutical and biotechnology companies, increasing adoption of the newest technologies, and recognized healthcare infrastructure. The U.S. is the leading biomarker market in North America, which might list the highest CAGR in the years ahead.
The Asia Pacific region is predictable to record high development in the biomarkers markets internationally in the years ahead. The rising frequencies of chronic diseases like cancer, neurological disorders, and cardiovascular diseases, rising support of the local governments for drug discovery and growth programs, quickening biomarkers mindfulness for disease analysis, and large patient pool are the significant elements boosting the biomarkers market development in the Asia Pacific. China, Japan, and India are forecast to be major funders to the Asia Pacific biomarkers market in the future. The favorable environment for clinical trials in the Asia Pacific is likely to fuel the biomarkers market over the prediction period.
Qiagen N.V., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Merck KGaA, Bio-Rad Laboratories, Abbott Laboratories, EKF Diagnostics, Enzo Biochem Inc., Meso Scale Diagnostics, LLC, Diagnosis, and PerkinElmer Inc. and other prominent players.
2020: F. Hoffmann-La Roche Ltd announced the approval by the US Food and Drug Administration (FDA) for its CINtec PLUS Cytology as the first biomarker-based triage test for women. Primary cervical cancer screening results are favorable for the human papillomavirus (HPV) using the Cobas 4800 HPV Test.
2018: Evidation Health announced the launch of their new project DisCover which
is a 10,000-person chronic pain study. The key aim is to use activity trackers,
health apps, and other more traditional data points and develop a digital
biomarker for chronic pains.
of the Report
By Disease Indication
Discovery and Development
East & Africa
The objective of the Study:
analyze and forecast the Global Biomarkers Market size of the market in terms
Ø To examine the careful market segmentation and forecast the market size, in terms of value, based on the region by segmenting the Global Biomarkers Market. It falls into five parts, namely, North America, Europe, Asia Pacific, Middle East, South America, and their leading countries.
outline, categorized forecast the Global Biomarkers Market based on the
Product, Type, By Disease Indication, By Application, and Regional.
examine competitive developments like Product, Type, Disease Indication, Application,
and Region within the Global Biomarkers Market.
highlight the impact analysis of the factors affecting the market dynamics.
strategically profile the key players and comprehensively analyze their market
shares along with detailing the competitive landscape for market leaders.
Questions Answered by the
Ø How will the market drivers, restraints, and opportunities
affect the market dynamics?
Ø What will be the market size in terms of value and volume and
market statistics with a detailed classification?
Ø Which segment dominates the market or region, and which one will
be the fastest-growing, and why?
Ø Who are the key players in the market, and what is their share?
Ø What is the strategy adopted by key players, and how does it
affect the existing and new players?
Customization Scope for the Client:
Client satisfaction is our first and last priority, and that is
why BlueWeave Consulting offers customization as per the client’s specific needs.
The following customization options are available for the report:
Ø Additional Company Information
Ø Detail Analysis of five additional companies
Ø Additional country analysis
Ø Detailed segment analysis
Historical data – 2016-2018
Base Year – 2019
Forecast – 2020 – 2026
Revenue in USD Billion
Canada, Germany, UK, France, Italy, Spain, Brazil, Mexico, Japan, South
Korea, China, India, South Korea UAE, South Africa, Saudi Arabia.
By Product, By
Type, By Disease Indication, By Application, and By Region
N.V., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer
Inc., Merck KGaA, Bio-Rad Laboratories, Abbott Laboratories, EKF Diagnostics,
Enzo Biochem Inc., Meso Scale Diagnostics, LLC, Diagnosis, and PerkinElmer
Inc. and other prominent players.